Company Overview
Carlsmed, Inc. operates as a commercial-stage medical technology company dedicated to designing, manufacturing, and marketing AI-enabled personalized spine surgery solutions. The firm focuses on the development of aprevo, a comprehensive technology platform specifically engineered for spine fusion surgery procedures that incorporates proprietary surgical tools. This business model places the company within the Healthcare sector, specifically the Health Information Services industry, where it leverages advanced technology to support complex surgical interventions. The organization employs a workforce of 127 individuals to execute its mission of advancing spine surgery through artificial intelligence integration. With a market capitalization of $269.99M and trailing twelve-month revenue of $50.51M, the company represents a mid-cap entity in its niche. These valuation and revenue figures indicate that Carlsmed holds a significant position within a specialized segment, balancing the high costs of medical technology development with substantial market demand for precision spine care solutions.
Financial Health
The company reported revenue of $50.51M over the trailing twelve months, yet recorded a net income of $-30,218,000 and an EBITDA of $-30,293,000, revealing a cost structure where expenses significantly outpace top-line growth. This substantial gap between revenue and profitability suggests the company is currently in an investment phase where research, development, and operational scaling costs are not yet covered by current earnings. Free cash flow stands at $-21,646,500, indicating that the company is consuming cash rather than generating it, which limits immediate financial flexibility but may be necessary for long-term product maturation. The gross margin is reported at 75.3%, reflecting high efficiency in production or pricing power, whereas the operating margin is -61.4% and the profit margin is -58.7%, highlighting significant operating expenses relative to sales. On the balance sheet, the company holds $109.79M in cash against $17.41M in debt, resulting in a debt-to-equity ratio of 17.61, which implies a highly leveraged structure in terms of equity but is mitigated by the substantial cash hoard. The current ratio of 8.87 indicates robust short-term liquidity, suggesting the firm can easily meet its immediate obligations with its current assets. Return on Equity is -47.6% and Return on Assets is -21.0%, metrics that reveal management is currently generating negative returns on the capital deployed, a common characteristic of pre-profitability growth-stage biotech or medtech firms.
Valuation Assessment
Valuation multiples for Carlsmed show a trailing P/E ratio of N/A due to losses, while the forward P/E is listed as -6.80, implying that the market expects earnings to remain negative or volatile in the near term. The price-to-book ratio stands at 2.72, indicating that the market values the company at a 172% premium over its book value, which often reflects intangible assets like intellectual property and future growth potential. Alternative valuation metrics include a price-to-sales ratio of 5.35 and an EV/EBITDA of -5.86, suggesting the market is pricing the stock based on revenue generation and cash position rather than current profitability. The 52-week trading range spans from a low of $9.80 to a high of $17.19, providing a context for price volatility and historical performance bounds. Without a specific current price provided in the data, the exact percentage below the high cannot be calculated, but the wide range between $9.80 and $17.19 demonstrates significant intrayear price movement. The beta value is N/A, meaning volatility relative to the broader market is not quantified in the available data, preventing a direct comparison to market risk.
Growth & Income
Revenue growth is reported at 61.2% year-over-year, demonstrating aggressive expansion in sales, while earnings growth is N/A due to the company's negative net income. The disparity between positive revenue growth and absent earnings growth implies that top-line expansion is outpacing profitability, a typical dynamic for companies scaling operations before achieving break-even. Regarding dividends, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute dividends to shareholders. This non-dividend status indicates that the company retains all earnings to reinvest into growth initiatives, R&D, and balance sheet strengthening rather than providing passive income. The overall growth and income profile is characterized by high revenue acceleration and zero income distribution, positioning the stock as a pure-play growth vehicle for investors seeking exposure to AI in spine surgery without the expectation of current cash returns.